Publicaciones en colaboración con investigadores/as de Novartis (Sweden) (119)

2024

  1. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 192-204

  2. Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 180-191

  3. Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial

    Lung Cancer, Vol. 189

  4. Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma

    Leukemia and Lymphoma, Vol. 65, Núm. 3, pp. 323-332

  5. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

    Blood

  6. Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet

    Pharmacological Research, Vol. 200

2023

  1. Clinical, methodology, and patient/carer expert advice in pediatric drug development by conect4children

    Clinical and Translational Science, Vol. 16, Núm. 3, pp. 478-488

  2. Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis

    Digital Health, Vol. 9

  3. Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy

    Kidney International Reports, Vol. 8, Núm. 12, pp. 2754-2764

  4. Female Sex, Age, and Unfavorable Response to Tumor Necrosis Factor Inhibitors in Patients With Axial Spondyloarthritis: Results of Statistical and Artificial Intelligence–Based Data Analyses of a National Multicenter Prospective Registry

    Arthritis Care and Research, Vol. 75, Núm. 1, pp. 115-124

  5. Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-α production and FOXP3+ Treg generation

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 4, pp. 1060-1072

  6. Non-invasive candidate protein signature predicts hepatic venous pressure gradient reduction in cirrhotic patients after sustained virologic response

    Liver International, Vol. 43, Núm. 9, pp. 1984-1994

  7. Omalizumab in IgE-Mediated Food Allergy: A Systematic Review and Meta-Analysis

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 4, pp. 1134-1146

  8. Patient-reported burden and overall impact of dry eye disease across eight European countries: a cross-sectional web-based survey

    BMJ Open, Vol. 13, Núm. 3

  9. Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 5, pp. 1004-1016

  10. Strategies to facilitate adolescent access to medicines: Improving regulatory guidance

    Clinical Trials, Vol. 20, Núm. 1, pp. 13-21

2022

  1. A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors

    Molecular Cancer Therapeutics, Vol. 21, Núm. 4, pp. 625-634

  2. An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients

    Transplantation Reviews, Vol. 36, Núm. 1

  3. Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (Breast Cancer Research and Treatment, (2021), 189, 3, (689-699), 10.1007/s10549-021-06334-0)

    Breast Cancer Research and Treatment

  4. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma

    Blood Advances, Vol. 6, Núm. 22, pp. 5835-5843